QCG
MCRB icon

Quadrant Capital Group’s Seres Therapeutics MCRB Stock Holding History

Quadrant Capital Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44
Closed -$2.1K – 2746
2023
Q3 		$2.1K Buy
+44
New +$3.36K ﹤0.01% 2377
2023
Q2 		– Sell
-105
Closed -$11.9K – 2738
2023
Q1 		$11.9K Buy
+105
New +$11.4K ﹤0.01% 1950
2022
Q2 		– Sell
-4
Closed -$1K – 2652
2022
Q1 		$1K Hold
4
– – ﹤0.01% 2340
2021
Q4 		$1K Hold
4
– – ﹤0.01% 2336
2021
Q3 		$1K Buy
+4
New +$783 ﹤0.01% 2341

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's MCRB Position: Q4 2023 in Review

Quadrant Capital Group sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 44 shares — an estimated $2.1K sold.

Quadrant Capital Group first reported a position in MCRB in Q3 2021 and held it in 5 quarters. The position peaked at $11.9K in Q1 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Quadrant Capital Group reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 44 Seres Therapeutics shares in Q4 2023, an estimated $2.1K.
  • Quadrant Capital Group first reported a position in Seres Therapeutics in Q3 2021 and held it in 5 quarters.
  • Quadrant Capital Group's Seres Therapeutics position peaked at $11.9K in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.